Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

British journal of cancer - 1 Aug 1999

Pratesi G, Perego P, Polizzi D, Righetti S C, Supino R, Caserini C, Manzotti C, Giuliani F C, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F

Abstract excerpt

Multinuclear platinum compounds were rationally designed to bind to DNA in a different manner from that of cisplatin and its mononuclear analogues. A triplatinum compound of the series (BBR 3464) was selected for preclinical development, since, in spite of its charged nature, it was very potent as cytotoxic agent and effective against cisplatin-resistant tumour cells. Anti-tumour efficacy studies were performed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Molecular Conformation

Share to Organoplatinum Compounds

Share to Osteosarcoma

Share to Polymorphism, Single-Stranded Conformational

Share to Transplantation, Heterologous

Source

Open in PubMed Open full text

Identifiers

PMID: 10471039
DOI: 10.1038/sj.bjc.6690620
PMCID: PMC2363141

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.PMID 10471039Read ↗

Mutant p53 as a target for cancer treatment.Semantic proximity Read ↗

Novel Approaches Towards Development of Non-Classical Platinum-Based Antineoplastic Agents: Design of Platinum Complexes Characterized by an Alternative DNA-Binding Pattern and/or Tumor-Targeted CytotoxicitySemantic proximity Read ↗

Molecular analysis of DNA damage induced by a novel trinuclear platinum complex (BBR 3464)Semantic proximity Read ↗

A kinetically inert platinum antitumor agent overcomes mutant p53-driven chemoresistance via oxidative stress-mediated DNA damage.Semantic proximity Read ↗

Mechanisms Controlling Sensitivity to Platinum Complexes: Role of p53 and DNA Mismatch RepairSemantic proximity Read ↗

Development of resistance to a trinuclear platinum complex in ovarian carcinoma cellsSemantic proximity Read ↗

Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.Semantic proximity Read ↗

Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties.Semantic proximity Read ↗

Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin.Semantic proximity Read ↗

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.Semantic proximity Read ↗

Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?Semantic proximity Read ↗

Third row transition metals for the treatment of cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.